Related Experiment Videos
Animal models: the in-vivo evaluation of ciprofloxacin
Abstract:
Ciprofloxacin has been extensively investigated in various animal models of infection. These studies have demonstrated ciprofloxacin to possess in-vivo activity comparable to its activity previously demonstrated in vitro. The reported investigations have shown ciprofloxacin to be equal or superior to all other agents tested for Gram-negative, as well as most Gram-positive bacteria. These studies have also demonstrated that in-vitro susceptibility testing correlates well with in-vivo therapeutic outcome, in the animal models. The reported information has provided new directions for use of this agent, including the possibility for the use of ciprofloxacin as a replacement for aminoglycosides in combination therapy of serious enterococcal infections.
Insights
Ciprofloxacin shows strong in-vivo antibacterial activity against Gram-negative and Gram-positive bacteria, matching or exceeding other tested agents. In-vitro susceptibility testing effectively predicts therapeutic outcomes in animal infection models.
Area of Science:
- Pharmacology and Microbiology
- Infectious Diseases
Background:
- Ciprofloxacin is a fluoroquinolone antibiotic with known antimicrobial properties.
- Previous research has established its efficacy in vitro.
Purpose of the Study:
- To evaluate the in-vivo efficacy of ciprofloxacin in various animal infection models.
- To compare ciprofloxacin's performance against other antimicrobial agents.
- To assess the correlation between in-vitro susceptibility and in-vivo therapeutic outcomes.
Main Methods:
- Infection was induced in animal models.
- Ciprofloxacin and other antimicrobial agents were administered.
- In-vivo efficacy was assessed.
- In-vitro susceptibility testing was performed.
- Correlation between in-vitro and in-vivo data was analyzed.
Main Results:
- Ciprofloxacin demonstrated significant in-vivo activity comparable to its in-vitro effectiveness.
- Ciprofloxacin was found to be equal or superior to other agents against Gram-negative and most Gram-positive bacteria.
- A strong correlation was observed between in-vitro susceptibility results and in-vivo therapeutic outcomes in animal models.
Conclusions:
- Ciprofloxacin exhibits robust in-vivo efficacy in animal models.
- In-vitro susceptibility testing is a reliable predictor of ciprofloxacin's therapeutic success.
- Findings support the potential use of ciprofloxacin as a replacement for aminoglycosides in treating serious enterococcal infections.